EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 178 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $0 | – | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 8 | -92.0% | 0.00% | – |
| Q3 2019 | $6,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $6,000 | +20.0% | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +25.0% | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $4,000 | -60.0% | 100 | -33.3% | 0.00% | -100.0% |
| Q3 2018 | $10,000 | -50.0% | 150 | -40.0% | 0.00% | -50.0% |
| Q2 2018 | $20,000 | -71.8% | 250 | -81.5% | 0.00% | -66.7% |
| Q1 2018 | $71,000 | -38.3% | 1,350 | -37.2% | 0.01% | -40.0% |
| Q4 2017 | $115,000 | -86.2% | 2,150 | -84.6% | 0.01% | -89.5% |
| Q3 2017 | $833,000 | -13.6% | 13,975 | +14.3% | 0.10% | -24.6% |
| Q2 2017 | $964,000 | +45.2% | 12,225 | +52.8% | 0.13% | +31.2% |
| Q1 2017 | $664,000 | – | 8,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |